|
|
|
|
La Jolla Pharmaceutical Company ("La Jolla") is dedicated to improving and preserving human life by developing innovative pharmaceutical products. The Company's leading product in development is Riquent®, which is designed to treat lupus renal disease by preventing or delaying renal flares. Lupus renal disease is a leading cause of sickness and death in patients with lupus. The Company has also developed small molecules to treat various other autoimmune and inflammatory conditions.
|
Lupus Clinical Trial: For information on the ASPEN Phase 3 study (Abetimus Sodium in Patients with a History of Lupus Nephritis), the ongoing Phase 3 study of Riquent (abetimus sodium), please go to the following website: clinicaltrials.gov
|
|
|
Terms of Use & Privacy Policy
Copyright © 2008, La Jolla Pharmaceutical Company
|
|
|
|
|
|